KC
UTHR icon

Kepos Capital’s United Therapeutics UTHR Stock Holding History

Kepos Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,208
Closed -$987K – 310
2019
Q4 		$987K Buy
11,208
+2,057
+22% +$181K 0.09% 139
2019
Q3 		$730K Sell
9,151
-19,450
-68% -$1.57M 0.07% 155
2019
Q2 		$2.23M Sell
28,601
-27,725
-49% -$2.59M 0.23% 101
2019
Q1 		$6.61M Buy
56,326
+1,814
+3% +$211K 0.5% 40
2018
Q4 		$5.94M Hold
54,512
– – 0.46% 58
2018
Q3 		$6.97M Buy
54,512
+30,797
+130% +$3.81M 0.36% 40
2018
Q2 		$2.68M Hold
23,715
– – 0.14% 141
2018
Q1 		$2.67M Buy
23,715
+4,161
+21% +$529K 0.16% 124
2017
Q4 		$2.89M Buy
19,554
+6,114
+45% +$777K 0.26% 103
2017
Q3 		$1.57M Buy
+13,440
New +$1.72M 0.26% 43

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Kepos Capital's UTHR Position: Q1 2020 in Review

Kepos Capital sold out of United Therapeutics (UTHR) in Q1 2020, closing a stake of 11,208 shares — an estimated $987K sold.

Kepos Capital first reported a position in UTHR in Q3 2017 and held it in 10 quarters. The position peaked at $6.97M in Q3 2018. 303 funds tracked by Wall St. Rank hold UTHR as of Q1 2020.

  • Kepos Capital reported no remaining United Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Kepos Capital sold 11,208 United Therapeutics shares in Q1 2020, an estimated $987K.
  • Kepos Capital first reported a position in United Therapeutics in Q3 2017 and held it in 10 quarters.
  • Kepos Capital's United Therapeutics position peaked at $6.97M in Q3 2018.
  • 303 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2020.

Based on Kepos Capital's 13F filing for Q1 2020, filed 12 May 2020.